Home › Psychotic Disorders › NCT04368039
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
Recruiting
Who can join
Ages 15 to 35 · All sexes
Full eligibility criteria
* Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5. * Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory . * No evidence of a pre-existing intellectual disability defined as a premorbid IQ \>70 as estimated using the Reading subtest of the Wide Range Achievement Test-4. * Ages 15-35 * Non-smoker for past six months * Absence of suicidal ideation or behavior over the past month as assessed by the Columbia Suicide Severity Rating Scale * The American Association for Respiratory Care notes that "no absolute contraindications to oxygen therapy exist when indications \[for oxygen therapy\] are present."
About the study
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
What is being tested
- Normobaric Oxygen (device)
- Placebo (device)
Sponsor: Nicholas Breitborde · Participants: 20 · Started: Dec 4, 2019
Contact the study team
- Nicholas Breitborde, PhD · Phone: (614) 685-6052
Official record on ClinicalTrials.gov — NCT04368039
Locations in the U.S.
| Ohio | Harding Hospital, Columbus |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.